Trial Outcomes & Findings for A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (NCT NCT01796171)
NCT ID: NCT01796171
Last Updated: 2024-06-21
Results Overview
Number of participants with dose limiting toxicities (DLTs) in Part A
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
191 participants
Primary outcome timeframe
12 weeks
Results posted on
2024-06-21
Participant Flow
Patients were recruited in the Australia, Canada, the European Union, Israel, Norway, Singapore, Turkey, United Kingdom (UK) and United States (US)
255 patients were screened in the 28 days before the start of treatment, 191 were enrolled, 190 started pre-treatment with rituximab (one enrolled participant died before starting rituximab) and 187 were treated with Betalutin
Participant milestones
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
Part A Received Rituximab Only
Did not receive pre-dosing or Betalutin
|
Part B, Arm 1 and Part C: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
These two groups were combined for analysis and reporting as they were run in parallel and participants received the same treatment
|
Part B, Arm 2: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part B, Arm 3: 12.5 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
40 mg lilotomab
12.5 mBq/kg Betalutin
|
Part B Received Rituximab Only
Did not receive pre-dosing or Betalutin
|
Enrolled But Not Treated
Participants were enrolled but did not receive any study treatment
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Enrolled
STARTED
|
4
|
36
|
3
|
1
|
2
|
3
|
3
|
18
|
4
|
2
|
76
|
28
|
9
|
1
|
1
|
|
Enrolled
COMPLETED
|
4
|
36
|
3
|
1
|
2
|
3
|
3
|
18
|
4
|
2
|
76
|
28
|
9
|
1
|
0
|
|
Enrolled
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Pre-reatment With Rituximab
STARTED
|
4
|
36
|
3
|
1
|
2
|
3
|
3
|
18
|
4
|
2
|
76
|
28
|
9
|
1
|
0
|
|
Pre-reatment With Rituximab
COMPLETED
|
4
|
36
|
3
|
1
|
2
|
3
|
3
|
18
|
4
|
0
|
76
|
28
|
9
|
0
|
0
|
|
Pre-reatment With Rituximab
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
1
|
0
|
|
Treatment Period With Betalutin
STARTED
|
4
|
36
|
3
|
1
|
2
|
3
|
3
|
18
|
4
|
0
|
76
|
28
|
9
|
0
|
0
|
|
Treatment Period With Betalutin
COMPLETED
|
4
|
35
|
3
|
1
|
2
|
3
|
3
|
18
|
3
|
0
|
65
|
25
|
8
|
0
|
0
|
|
Treatment Period With Betalutin
NOT COMPLETED
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
11
|
3
|
1
|
0
|
0
|
|
Follow-up Period
STARTED
|
4
|
35
|
3
|
1
|
2
|
3
|
3
|
18
|
3
|
0
|
65
|
25
|
8
|
0
|
0
|
|
Follow-up Period
COMPLETED
|
0
|
5
|
1
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Follow-up Period
NOT COMPLETED
|
4
|
30
|
2
|
1
|
2
|
3
|
2
|
18
|
2
|
0
|
65
|
25
|
8
|
0
|
0
|
Reasons for withdrawal
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
Part A Received Rituximab Only
Did not receive pre-dosing or Betalutin
|
Part B, Arm 1 and Part C: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
These two groups were combined for analysis and reporting as they were run in parallel and participants received the same treatment
|
Part B, Arm 2: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part B, Arm 3: 12.5 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
40 mg lilotomab
12.5 mBq/kg Betalutin
|
Part B Received Rituximab Only
Did not receive pre-dosing or Betalutin
|
Enrolled But Not Treated
Participants were enrolled but did not receive any study treatment
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Enrolled
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Pre-reatment With Rituximab
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
|
Pre-reatment With Rituximab
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Treatment Period With Betalutin
Progressive disease
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period With Betalutin
Start of further anticancer therapy
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Treatment Period With Betalutin
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
1
|
1
|
0
|
0
|
|
Treatment Period With Betalutin
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Treatment Period With Betalutin
Sponsor Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Treatment Period With Betalutin
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Follow-up Period
Start of further anticancer therapy
|
4
|
25
|
2
|
1
|
2
|
2
|
1
|
15
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Follow-up Period
Progressive disease
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Follow-up Period
Physician Decision
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
0
|
|
Follow-up Period
Withdrawal by Subject
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
3
|
1
|
0
|
0
|
0
|
|
Follow-up Period
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
17
|
9
|
1
|
0
|
0
|
|
Follow-up Period
Patient transferred to other hospital
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Follow-up Period
Sponsor Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
40
|
15
|
7
|
0
|
0
|
Baseline Characteristics
A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Baseline characteristics by cohort
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=4 Participants
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=36 Participants
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=3 Participants
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
n=1 Participants
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
n=2 Participants
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
n=3 Participants
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=3 Participants
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=19 Participants
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
n=3 Participants
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
Part A - Received Rituximab Only
n=2 Participants
Participant received pre-treatment only and was withdrawn before receiving Betalutin
|
Part B Arm 1 and Part and C: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=76 Participants
15 MBq/kg Betalutin
40 mg lilotomab
Note: these two groups were combined for the purposes of the safety analyses as they received the same treatment therefore have been combined for the purposes of reporting baseline variables for consistency
|
Part B, Arm 2: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=28 Participants
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part B, Arm 3: 12.5 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=9 Participants
40 mg lilotomab
12.5 mBq/kg Betalutin
|
Part B - Received Rituximab Only
n=1 Participants
Participant received pre-treatment only and was withdrawn before receiving Betalutin
|
Total
n=190 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=16 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2 Participants
n=5 Participants
|
11 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
4 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
29 Participants
n=17 Participants
|
9 Participants
n=21 Participants
|
4 Participants
n=22 Participants
|
1 Participants
n=8 Participants
|
63 Participants
n=16 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=5 Participants
|
25 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
15 Participants
n=6 Participants
|
2 Participants
n=6 Participants
|
2 Participants
n=64 Participants
|
47 Participants
n=17 Participants
|
19 Participants
n=21 Participants
|
5 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
127 Participants
n=16 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
2 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
9 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
2 Participants
n=64 Participants
|
46 Participants
n=17 Participants
|
16 Participants
n=21 Participants
|
3 Participants
n=22 Participants
|
1 Participants
n=8 Participants
|
101 Participants
n=16 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=10 Participants
|
3 Participants
n=115 Participants
|
10 Participants
n=6 Participants
|
2 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
30 Participants
n=17 Participants
|
12 Participants
n=21 Participants
|
6 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
89 Participants
n=16 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=16 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=16 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=16 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=16 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=5 Participants
|
36 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=10 Participants
|
3 Participants
n=115 Participants
|
19 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
2 Participants
n=64 Participants
|
73 Participants
n=17 Participants
|
23 Participants
n=21 Participants
|
9 Participants
n=22 Participants
|
1 Participants
n=8 Participants
|
182 Participants
n=16 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=16 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=64 Participants
|
3 Participants
n=17 Participants
|
4 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
7 Participants
n=16 Participants
|
PRIMARY outcome
Timeframe: 12 weeksPopulation: Population evaluable for DLTs. Note one further participant was treated with 20 MBq Betalutin and 100 mg/m2 lilotomab but was underdosed with lilotomab so was not evaluable for DLTs and has not been included.
Number of participants with dose limiting toxicities (DLTs) in Part A
Outcome measures
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=4 Participants
10 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=6 Participants
15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=3 Participants
20 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
n=1 Participants
10 MBq/kg (based on body weight) Betalutin without pre-dosing
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
n=2 Participants
15 MBq/kg (based on body weight) Betalutin without pre-dosing
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
n=3 Participants
15 MBq/kg (based on body weight) Betalutin with rituximab pre-dosing
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=3 Participants
15 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=6 Participants
20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
n=3 Participants
20 MBq/kg (based on body weight) Betalutin with 60 mg/m2 (based on body surface area) lilotomab pre-dosing
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
|---|---|---|---|---|---|---|---|---|---|
|
Part A, Phase I
|
0 Participants
|
1 Participants
|
3 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 5 yearsPopulation: Per-protocol analysis set: participants receiving Betalutin who had adequate tumour assessments at baseline, and after ≥12 weeks (unless disease progression occurred), and no major protocol deviations impacting on efficacy results. Only participants in Phase IIa with FL receiving 40/15 and 100/20 With FL were analyzed. This was the analysis set selected for efficacy analysis as this was the population selected for further analysis in the larger Part B study.
Tumour response rates in patients in Part A receiving Betalutin based on evaluation of CT scan images including PET/CT imaging (and bone marrow biopsy if applicable).
Outcome measures
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=18 Participants
10 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=9 Participants
15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
20 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
10 MBq/kg (based on body weight) Betalutin without pre-dosing
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
15 MBq/kg (based on body weight) Betalutin without pre-dosing
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
15 MBq/kg (based on body weight) Betalutin with rituximab pre-dosing
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
15 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
20 MBq/kg (based on body weight) Betalutin with 60 mg/m2 (based on body surface area) lilotomab pre-dosing
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
|---|---|---|---|---|---|---|---|---|---|
|
Part A, Phase IIa
Complete remission
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part A, Phase IIa
Partial remission
|
5 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part A, Phase IIa
Stable disease
|
3 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Part A, Phase IIa
Progressive disease
|
3 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: up to 5 yearsOverall response rate in Part B defined as the number of participants with a best response of complete remission or partial remission at any time
Outcome measures
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=72 Participants
10 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=28 Participants
15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=9 Participants
20 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
10 MBq/kg (based on body weight) Betalutin without pre-dosing
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
15 MBq/kg (based on body weight) Betalutin without pre-dosing
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
15 MBq/kg (based on body weight) Betalutin with rituximab pre-dosing
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
15 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
20 MBq/kg (based on body weight) Betalutin with 60 mg/m2 (based on body surface area) lilotomab pre-dosing
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
|---|---|---|---|---|---|---|---|---|---|
|
Part B, Phase IIb
|
28 Participants
|
9 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
Serious events: 7 serious events
Other events: 36 other events
Deaths: 10 deaths
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
Serious events: 2 serious events
Other events: 2 other events
Deaths: 0 deaths
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
Serious events: 0 serious events
Other events: 16 other events
Deaths: 6 deaths
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
Serious events: 0 serious events
Other events: 4 other events
Deaths: 1 deaths
Part A Rituximab Only
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Part B Arm 1 and Part C: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
Serious events: 12 serious events
Other events: 61 other events
Deaths: 23 deaths
Part B Arm 2: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
Serious events: 7 serious events
Other events: 22 other events
Deaths: 11 deaths
Part B, Arm 3: 12.5 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
Serious events: 0 serious events
Other events: 9 other events
Deaths: 1 deaths
Part B Rituximab Only
Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths
Part B Not Treated
Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=4 participants at risk
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=36 participants at risk
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=3 participants at risk
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
n=1 participants at risk
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
n=2 participants at risk
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
n=3 participants at risk
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=3 participants at risk
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=18 participants at risk
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
n=4 participants at risk
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
Part A Rituximab Only
n=2 participants at risk
Did not receive pre-dosing or Betalutin
|
Part B Arm 1 and Part C: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=76 participants at risk
15 MBq/kg Betalutin
40 mg lilotomab
These two groups were combined for analysis and reporting as they were run in parallel and participants received the same treatment
|
Part B Arm 2: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=28 participants at risk
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part B, Arm 3: 12.5 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=9 participants at risk
12.5 mBq/kg Betalutin
40 mg lilotomab
|
Part B Rituximab Only
n=1 participants at risk
Did not receive pre-dosing or Betalutin
|
Part B Not Treated
n=1 participants at risk
Enrolled but died before receiving rituximab
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
COVID-19
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukemia
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal neoplasm
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Pharygngitis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Pneumonia
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Sepsis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Platelet count decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Injury, poisoning and procedural complications
Sternal fracture
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Fungaemia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Pleural infection bacterial
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Tooth abscess
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
squamous cell carcinoma of the skin
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Ileal perforation
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Malaise
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Injury, poisoning and procedural complications
Radiation pneumonitis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Nervous system disorders
Presyncope
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Device related infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
—
0/0 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
Other adverse events
| Measure |
Part A, Arm 1: 10 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=4 participants at risk
10 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=36 participants at risk
15 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 1: 20 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=3 participants at risk
20 MBq/kg Betalutin
40 mg lilotomab
|
Part A, Arm 2: 10 MBq/kg Betalutin With no Pre-dosing
n=1 participants at risk
10 MBq/kg Betalutin
|
Part A, Arm 2: 15 MBq/kg Betalutin With no Pre-dosing
n=2 participants at risk
15 MBq/kg Betalutin
|
Part A, Arm 3: 15 MBq/kg Betalutin With Rituximab Pre-dosing
n=3 participants at risk
15 MBq/kg Betalutin
Rituximab
|
Part A, Arm 4: 15 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=3 participants at risk
15 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 4: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=18 participants at risk
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part A, Arm 5: 20 MBq/kg Betalutin With Intermediate Dose Lilotomab Pre-dosing
n=4 participants at risk
20 MBq/kg Betalutin
60 mg/m2 lilotomab
|
Part A Rituximab Only
n=2 participants at risk
Did not receive pre-dosing or Betalutin
|
Part B Arm 1 and Part C: 15 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=76 participants at risk
15 MBq/kg Betalutin
40 mg lilotomab
These two groups were combined for analysis and reporting as they were run in parallel and participants received the same treatment
|
Part B Arm 2: 20 MBq/kg Betalutin With Higher Dose Lilotomab Pre-dosing
n=28 participants at risk
20 MBq/kg Betalutin
100 mg/m2 lilotomab
|
Part B, Arm 3: 12.5 MBq/kg Betalutin With Lower Dose Lilotomab Pre-dosing
n=9 participants at risk
12.5 mBq/kg Betalutin
40 mg lilotomab
|
Part B Rituximab Only
n=1 participants at risk
Did not receive pre-dosing or Betalutin
|
Part B Not Treated
n=1 participants at risk
Enrolled but died before receiving rituximab
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
17.9%
5/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Coccydynia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Neutropenia
|
50.0%
2/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
55.6%
20/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
27.8%
5/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
15.8%
12/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.7%
3/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
3/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
52.8%
19/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
22.2%
4/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
17.1%
13/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.7%
3/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
3/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Leukopenia
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
38.9%
14/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Lymphopenia
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
27.8%
10/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Blood creatinine increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
8.3%
3/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
15.8%
12/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
21.4%
6/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
22.2%
2/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
8.3%
3/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
2/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Blood and lymphatic system disorders
Lymphocytosis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
13.9%
5/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Nasopharyngitis
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
16.7%
3/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
8.3%
3/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Bronchitis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Oral herpes
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Rhinitis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
White blood cell count decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
13.9%
5/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
3/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
2/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
3/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
66.7%
2/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
16.7%
3/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
2/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
8.3%
3/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
3/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
3/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
66.7%
2/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
16.7%
3/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.9%
6/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Platelet count decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
4/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
66.7%
2/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
66.7%
2/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
22.2%
4/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.5%
8/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.7%
3/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
3/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
22.2%
4/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Blood lactate dehydrogenase decreased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Metabolism and nutrition disorders
Decreased appetitie
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Cardiac murmur
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Nausea
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
13.9%
5/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
2/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
2/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
13.2%
10/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Diarrhoea
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.5%
8/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
66.7%
2/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Abdominal pain
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.9%
6/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.7%
3/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
6.6%
5/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Tongue coated
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
8.3%
3/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicular lymphoma
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Fatigue
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
14.5%
11/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.7%
3/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
22.2%
2/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Influenza like illness
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Asthenia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Axillary pain
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Oedema
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Oedema peripheral
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
10.7%
3/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Pain
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
4/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
6.6%
5/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
14.3%
4/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Hypermobility syndrome
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Rash macropapular
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
6.6%
5/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Skin burning sensation
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
2/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Nervous system disorders
Dizziness
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
4/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Nervous system disorders
Headache
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Nervous system disorders
Hypersomnia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Vascular disorders
Haematoma
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.6%
1/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Vascular disorders
Hot flush
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
50.0%
1/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
33.3%
1/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
COVID-19
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Infections and infestations
Infection
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
6.6%
5/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Injury, poisoning and procedural complications
Dose calculation error
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Percussion test abnormal
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Blood urea increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Investigations
Blood uric acid increased
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
General disorders
Chills
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
1/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.3%
4/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
7.1%
2/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
5.6%
2/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
3.9%
3/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
1.3%
1/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
11.1%
1/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.8%
1/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
25.0%
1/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
2.6%
2/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
|
Psychiatric disorders
Alcohol abuse
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/36 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/3 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/18 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/4 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/2 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/76 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/28 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/9 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
100.0%
1/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
0.00%
0/1 • Adverse events were collected from informed consent up to 12 weeks after Betalutin administration (note: in Part A SAEs only were collected between informed consent and rituximab administration; in Parts B and C all adverse events were collected in this period). Treatment-related adverse events were then collected up to 5 years (end of the study).
Summaries of adverse events were generated for all participants
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60